From CONSENSUS to CHARM - How do ACEI and ARB produce clinical benefits in CHF?

International Journal of Cardiology

Volumn 94, Issue 2-3, 2004, Pages 137-141

  Tan, L B ^a   Williams, S G ^b   Goldspink, D F ^c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

^c LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

ACE inhibitors; Angiotensin receptor blockers; Cardiac reserve; Cardiotoxicity; Chronic heart failure; Clinical trials; Longevity

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; CARDIOTOXIN; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; NEUROHORMONE;

CARDIOMYOPATHY; CLINICAL PRACTICE; CLINICAL TRIAL; COUGHING; DRUG EFFECT; DRUG SCREENING; EVIDENCE BASED MEDICINE; EXERCISE; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE REMODELING; HUMAN; MEDICAL RESEARCH; MYOCARDITIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 1842861649     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2003.10.004     Document Type: Editorial

References (59)

1. Pfeffer M.A., et al. for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 362:2003;759-766.
2. Granger C.B., et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 362:2003;772-776.
3. McMurray J.J.V., et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function talking angiotension converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 362:2003;767-771.
4. Yusuf S., et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet. 362:2003;777-781.
5. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Engl. J. Med. 316:1987;1429-1435.
6. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New Engl. J. Med. 342:2000;145-153.
7. The European Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 362:2003;782-788.
8. Nickenig G., Harrison D.G. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation. 105:2002;393-396.
9. Poole-Wilson P.A., Katz A.M. Future strategies of reverse remodelling: summation. J. Card. Fail. 8:(Suppl. 6):2002;S556-S561.
10. Brilla C.G., Pick R., Tan L.B., Janicki J.S., Weber K.T. Remodeling of the rat right and left ventricle in experimental hypertension. Circ. Res. 67:1990;1355-1364.
11. Brilla C.G., Funck R.C., Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 102:2000;1388-1393.
12. Stauss H.M., Zhu Y.C., Redlich T., Adamiak D., Mott A., Kregel K.C., et al. Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. J. Cardiovasc. Risk. 1:1994;255-262.
13. Gohlke P., Linz W., Scholkens B.A., Kuwer I., Bartenbach S., Schnell A., et al. Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin. Hypertension. 23:1994;411-418.
14. Hu K., Gaudron P., Anders H.J., Weidemann F., Turschner O., Nahrendorf M., et al. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin. Cardiovasc. Res. 39:1998;401-412.
15. Williams B. The renin angiotensin system and cardiovascular disease: hope or hype? J. Renin Angiotension Aldosterone System. 1:2000;142-146.
16. Svensson P., de Faire U., Sleight P., Yusuf S., Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension. 38:2001;E28-E32.
17. Lonn E. Modifying the natural history of atherosclerosis: the SECURE trial. Int. J. Clin. Pract. 117:2001;13-18.
18. Lonn E. ACE inhibitors and angiotensin receptor blockers in atherosclerosis. Curr. Atheroscler. Rep. 4:2002;363-372.
19. Halkin A., Keren G. Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease. Am. J. Med. 112:2002;126-134.
20. Harris P. Congestive cardiac failure: central role of the arterial blood pressure. Br. Heart J. 58:1987;190-203.
21. Harris P. Role of arterial pressure in the oedema of heart disease. Lancet. i:(8593):1988;1036-1038.
22. Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 82:1990;1730-1736.
23. Benedict C.R., Shelton B., Johnstone D.E., Francis G., Greenberg B., Konstam M., et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation. 94:1996;690-697.
24. Groenning B.A., Nilsson J.C., Sondergaard L., et al. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations. Eur. J. Heart Fail. 3:2001;699-708.
25. Dzau V.J. Mechanism of action of angiotensin-converting enzyme (ACE) inhibitors in hypertension and heart failure. Role of plasma versus tissue ACE. Drugs. 39:(Suppl. 2):1990;11-16.
26. Dzau V.J. Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. Basic Res. Cardiol. 88:(Suppl. 1):1993;1-14.
27. Dzau V.J., Bernstein K., Celermajer D., Cohen J., Dahlof B., Deanfield J., et al. Working Group on Tissue Angiotensin-converting Enzyme, International Society of Cardiovascular Pharmacotherapy. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am. J. Cardiol. 88:(Suppl. 9):2001;1L-20L.
28. Benjamin I.J., Jalil J.E., Tan L.B., Cho K., Weber K.T., Clark W.A. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ. Res. 65:1989;657-670.
29. Tan L.B., Benjamin I.J., Clark W.A. Beta-adrenergic receptor desensitization may serve a cardioprotective role. Cardiovasc. Res. 26:1992;608-614.
30. Tan L.B., Jalil J.E., Pick R., Janicki J.S., Weber K.T. Cardiac myocyte necrosis induced by angiotensin II. Circ. Res. 69:1991;1185-1195.
31. Rocha R., Stier C.T. Jr., Kifor I., Ochoa-Maya M.R., Rennke H.G., Williams G.H., et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 141:2000;3871-3878.
32. De Angelis N., Fiordaliso F., Latini R. Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rats. J. Mol. Cell. Cardiol. 34:2002;1655-1665.
33. Stier C.T. Jr., Chander P.N., Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol. Rev. 10:2002;97-107.
34. Ng Y., Goldspink D.F., Clark W.A., Colyer J., Tan L.B. Isoprenaline induces myocyte necrosis in rat skeletal muscle: comparison with effects on cardiomyocytes. Int. J. Cardiol. 86:2002;299-309.
35. Tan L.B., Burniston J.G., Clark W.A., Ng Y.L., Goldspink D.F. Characterisation of adrenoceptor involvement in skeletal and cardiac myotoxicity induced by sympathomimetic agents. J. Cardiovasc. Pharm. 41:2003;518-525.
36. Goldspink D.F., Burniston J.G., Tan L.B. Cardiomyocyte death and the ageing and failing heart. Exp. Physiol. 88:2003;447-458.
37. Metzger M., Higuchi M.L., Moreira L.F., Chaves M.J., Castelli J.B., Silvestre J.M., et al. Relevance of apoptosis and cell proliferation for survival of patients with dilated cardiomyopathy undergoing partial left ventriculectomy. Eur. J. Clin. Invest. 32:2002;394-399.
38. Saraste A., Pulkki K., Kallajoki M., Heikkila P., Laine P., Mattila S., et al. Cardiomyocyte apoptosis and progression of heart failure to transplantation. Eur. J. Clin. Invest. 29:1999;380-386.
39. Narula J., Haider N., Virmani R., DiSalvo T.G., Kolodgie F.D., Hajjar R.J., et al. Apoptosis in myocytes in end-stage heart failure. New Engl. J. Med. 335:1996;1182-1189.
40. Olivetti G., Melissari M., Capasso J.M., Anversa P. Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy. Circ. Res. 68:1991;1560-1568.
41. Goussev A., Sharov V.G., Shimoyama H., Tanimura M., Lesch M., Goldstein S., et al. Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure. Am. J. Physiol. 275:1998;H626-H631.
42. Sabbah H.N., Sharov V.G., Gupta R.C., Todor A., Singh V., Goldstein S. Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure. J. Am. Coll. Cardiol. 36:2000;1698-1705.
43. Kiowski W. Prejunctional modulation of sympathetic tone by angiotensin II receptor antagonists: are there relevant differences? J. Hypertens. 20:2002;1061-1063.
44. Cotter G., Williams S.G., Vered Z., Tan L.B. Role of cardiac power in heart failure. Curr. Opin. Cardiol. 18:2003;215-222.
45. Williams S.G., Cooke G.A., Wright D.J., Parsons W., Riley R.L., Marshall P., et al. Peak cardiac power output: a powerful prognostic indicator in chronic heart failure. Eur. Heart J. 22:2001;1496-1503.
46. Tan L.B., Murphy R. Shifts in mortality curves: saving or extending lives? Lancet. 354:1999;1378-1381.
47. Tan L.B., Schlosshan D. Applying mortality curves to general practice. Prescriber. 14:2003;65-69.
48. Pitt B., Poole-Wilson P.A., Segal R., Martinez F.A., Dickstein K., Camm A.J., et al. on the behalf of the ELITE II investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet. 355:2000;1582-1587.
49. Williams S.G., Cooke G.A., Wright D.J., Tan L.B. Disparate results of ACE inhibitor dosage on exercise capacity in heart failure: a reappraisal of vasodilator therapy and study design. Int. J. Cardiol. 77:2001;239-245.
50. Cooke G.A., Williams S.G., Marshall P., Al-Timman J.K., Shepherd J., Wright D.J., et al. A mechanistic investigation of ACE inhibitor dose effects on aerobic exercise capacity in heart failure patients. Eur. Heart J. 23:2002;1360-1368.
51. Tan L.B., Williams S.G., Wright D.J. Ventriculo-arterial function curves - a new dimension in characterising acute heart failure. Eur. J. Heart Fail. 5:2003;407-410.
52. Opie L.H., Sack M.N. Enhanced angiotensin II activity in heart failure: re-evaluation of the counterregulatory hypothesis of receptor subtypes. Circ. Res. 88:2001;654-658.
53. Lim D.-S., Lutucuta S., Bachireddy P., Youker K., Evans A., Entman M., et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 103:2001;789-791.
54. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 353:1999;9-13.
55. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 353:1999;2001-2007.
56. Packer M., Coats A.J., Fowler M.B., Katus H.A., Krum H., Mohacsi P., et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. New Engl. J. Med. 344:2001;1651-1658.
57. Pitt B., et al. for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl. J. Med. 341:1999;709-717.
58. Pitt B., et al. for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New Engl. J. Med. 348:2003;1309-1321. (Erratum in: New Engl. J. Med. 2003;348:2271).
59. Williams S.G., Tan L.B. Aldosterone antagonists: current and future perspectives. Curr. Opin. Cardiovasc. Pulmon. Renal Invest. Drugs. 2:2000;310-315.